AZA

Confiscated Tiger Cub Brought to Oakland Zoo for Long-Term Rehabilitation and Care

Retrieved on: 
星期五, 二月 23, 2024
Zoo, AZA, Big Cat Rescue, Education, Medicine, Pain, Animal, Female, Injury, Surgeon, Calcium, Hope, California Department, Tiger King, Commerce, Safety, History, Nutrient, Cat, Accreditation, Knowledge, Rehabilitation, Legal case, Fracture, Muscle atrophy, Breeding, Running

OAKLAND, Calif., Feb. 23, 2024 /PRNewswire-PRWeb/ -- On Tuesday afternoon, Oakland Zoo, acting as agents for the California Department of Fish and Wildlife, assisted with rescuing an eight-month-old female tiger from a privately owned facility in the western U.S. The female tiger was found to be suffering from numerous improperly healed fractures in her bones. Oakland Zoo's Veterinary Hospital staff performed a thorough physical exam, CT scan, and bloodwork. It was determined that the patient had ten pathological fractures, leading to pain and a lack of mobility. This led to a 50% muscle atrophy in her legs. She was supplemented with nutrients and given the necessary pain medication. "I've treated over 100 cases of rescued big cats, and unfortunately, these injuries can lead to lifelong medical issues," says Dr. Ryan Sadler, Senior Veterinarian at Oakland Zoo.The Zoo's Veterinary Hospital team is working to build her calcium and muscle growth, which can take several weeks to months. Once her bones have built enough calcium, the Zoo's Veterinarians will work with surgeons to determine the next steps in her healing journey. Oakland Zoo veterinarians are cautiously optimistic, though it will take some time, that she will make a full recovery.

Key Points: 
  • Now receiving specialized care at Oakland Zoo's Veterinary Hospital, the eight-month-old tiger has a hopeful future.
  • Oakland Zoo veterinarians are cautiously optimistic, though it will take some time, that she will make a full recovery.
  • We are grateful to serve in a role that gives her hope for brighter days ahead," says Nik Dehejia, CEO of Oakland Zoo.
  • With their expertise, knowledge, and exemplary standards of care, Oakland Zoo is equipped to execute the rehabilitation this rescued female tiger needs to begin her long journey to recovery.

IMMOTION JOINS THE ASSOCIATION OF ZOOS AND AQUARIUMS COMMERCIAL MEMBER ENGAGEMENT COUNCIL

Retrieved on: 
星期一, 一月 29, 2024
VR, Partnership, AZA, CMEC, Education, Element, Commercial

LOS ANGELES, Jan. 29, 2024 /PRNewswire/ -- Immotion, a global leader in immersive edutainment, is proud to announce its membership in the Association of Zoos and Aquariums (AZA) Commercial Member Engagement Council (CMEC).

Key Points: 
  • LOS ANGELES, Jan. 29, 2024 /PRNewswire/ -- Immotion, a global leader in immersive edutainment, is proud to announce its membership in the Association of Zoos and Aquariums (AZA) Commercial Member Engagement Council (CMEC).
  • This partnership aligns with our commitment to conservation education and our mission to spotlight endangered species.
  • By joining the CMEC, Immotion aims to further its commitment to these elements and contribute to AZA's mission.
  • Rod Findley, President & CEO of Immotion, expressed his enthusiasm about the new partnership: "We are thrilled to join the AZA's Commercial Member Engagement Council.

Denver Zoo Earns American Humane Certification for Animal Welfare

Retrieved on: 
星期二, 一月 23, 2024
Senior, Volunteering, Animal, Ethics, Health, Housing, Happiness, Zoo, Accreditation, Organization, Human, AZA, Elephant, Certification, American Humane

DENVER, Jan. 23, 2024 /PRNewswire-PRWeb/ -- American Humane, the United States' first national humane organization and the world's largest certifier of animal welfare practices, announced that Denver Zoo has again earned the American Humane Certified™ seal and another five-year certification for demonstrating outstanding welfare and treatment of the animals in its care. The Zoo passed a rigorous independent assessment to join a growing number of leading zoological institutions that have earned the American Humane Certified™ designation. This certification closely follows the Zoo's accreditation by the Association of Zoos and Aquariums (AZA) in 2023.

Key Points: 
  • DENVER, Jan. 23, 2024 /PRNewswire-PRWeb/ -- American Humane, the United States' first national humane organization and the world's largest certifier of animal welfare practices, announced that Denver Zoo has again earned the American Humane Certified™ seal and another five-year certification for demonstrating outstanding welfare and treatment of the animals in its care.
  • The Zoo passed a rigorous independent assessment to join a growing number of leading zoological institutions that have earned the American Humane Certified™ designation.
  • The American Humane Certified™ program is the world's first certification program dedicated solely to the welfare of animals in zoological institutions.
  • The program enforces rigorous, science-based and comprehensive criteria for animal welfare, developed by an independent Scientific Advisory Committee comprised of world-renowned leaders in the fields of animal science, animal behavior and animal ethics.

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024

Retrieved on: 
星期一, 一月 8, 2024
Autoimmune disease, Completeness, Ovarian cancer, PROC, AZA, TP53, Anemia, Society, Clinical trial, Cancer, Event, Azacitidine, Investment, Webcast, Patient, Safety, PLD, Acceleration, AML, Mirvetuximab soravtansine, Pharmaceutical industry

AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today provided a corporate update and highlighted upcoming key milestones anticipated in 2024.
  • “In 2023, we delivered key safety and efficacy data across our clinical development program for SL-172154 and further strengthened our financial resources, which we believe will carry us beyond upcoming milestones in the year ahead,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck Labs.
  • On December 21, 2023, Shattuck announced a $50 million registered offering of common stock and concurrent private placement of pre-funded warrants.
  • Initial combination data from the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected mid-year 2024.

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, MRI, INN, Contraindication, AZA, Axial spondyloarthritis, Rash, Tissue, ACR20, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Adolescence, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Nonsteroidal anti-inflammatory drug, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Select, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Child, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Liver, Marketing, MP, Heart, MRI, INN, Risk, MTX, Pneumonia, Fungus, AZA, UC, Eating, Inflammation, Ankylosing spondylitis, Infection, Fungal infection, Diagnosis, Anatomy, Ulcer, Lymphoma, IIA, Skin, Vasculitis, Yeast, Psoriasis, ATC, Joint, Pain, Psoriatic arthritis, Syringe, Disease, Nose, Allergy, Lower respiratory tract infection, Nonsteroidal anti-inflammatory drug, Hepatitis B virus, Safety, Heart failure, CRP, Disorder, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Leukemia, Patient, Medical Subject Headings, Walking, Immune system, Ulcerative colitis, International, Arthritis, Language, Blood, Hepatitis B, Medication package insert, Tuberculosis, Select, Medicine, Methotrexate, Azathioprine, TNF, X-ray, Mercaptopurine, European Medicines Agency, Spine, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, MRI, INN, Risk, Contraindication, AZA, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Disease-modifying antirheumatic drug, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Ageing, Blood, Safety, Heart failure, CRP, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hefiya, adalimumab, Date of authorisation: 26/07/2018, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Contraindication, AZA, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, Psoriasis, ATC, Joint, Crohn's disease, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Medicine, Methotrexate, Azathioprine, TNF, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Hyrimoz, adalimumab, Date of authorisation: 26/07/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, Contraindication, INN, Risk, AZA, Nausea, Heart, Inflammation, Disease-modifying antirheumatic drug, Infection, Diagnosis, Risk management, Anatomy, Ulcer, IIA, CHMP, Skin, Sinusitis, ATC, Joint, Pain, Psoriatic arthritis, Drainage, European, Disease, Ageing, Human, Safety, Heart failure, Rheumatoid arthritis, Medical Subject Headings, Agency, European Commission, Immune system, Ulcerative colitis, ACR, International, Arthritis, Language, Blood, Ciclosporin, Viral, Tuberculosis, Select, Patient, Medicine, Methotrexate, Azathioprine, Common, Tumor necrosis factor, Allergy, PUVA, Glycine mollis, Headache, Abdominal pain, Ankylosing spondylitis, Spine, Chronic pain, Committee, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Flixabi, infliximab, Date of authorisation: 26/05/2016, Revision: 24, Status: Authorised

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat

Retrieved on: 
星期三, 十二月 13, 2023
Patient, ALT, Clutch (eggs), Febrile neutropenia, Hypokalemia, Cardiac arrest, Autoimmune disease, Pneumonia, AZA, TP53, MCR, Anemia, CRi, Fatigue, Disease, Amiodarone, IRR, Clinical trial, Cancer, Morphology, Arrhythmia, ASH, Neutrophil, Combination therapy, Chondrocalcinosis, Observation, Hypoxia, Poster, Safety, AML, Pharmaceutical industry

AUSTIN, TX & DURHAM, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting.

Key Points: 
  • That patient remains disease free.” said Dr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck.
  • TP53m AML: In 11 evaluable patients with previously untreated TP53m AML, two patients achieved a CR.
  • Safety: Preliminary data suggest that SL-172154 has an acceptable safety and tolerability profile in combination with azacitidine.
  • To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website here .